Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Corcept To Test Sluggish IPO Market For Biotechs

  • News

Executive Summary

Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10

You may also be interested in...



ZymoGenetics/Serono Will Start Lupus Trials For TACI-Ig In 2nd Half Of 2003

ZymoGenetics will initiate clinical studies for its autoimmune disease agent TACI-Ig in systemic lupus erythematosis during the second half of 2003, the company said during its Dec. 3 analyst presentation in New York

ZymoGenetics/Serono Will Start Lupus Trials For TACI-Ig In 2nd Half Of 2003

ZymoGenetics will initiate clinical studies for its autoimmune disease agent TACI-Ig in systemic lupus erythematosis during the second half of 2003, the company said during its Dec. 3 analyst presentation in New York

Danco Mifeprex Patent Extension Will Be Revised After Corcept Objects

The patent life of Danco Labs/The Population Council's Mifeprex (mifepristone, RU-486) will be shortened following a determination by FDA that the abortifacient IND became "effective" in 1983 rather than 1994

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS039961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By